Ginkgo Bioworks Holdings (DNA) has issued an update.
A company has announced its noncompliance with NYSE listing standards and is exploring options to address the issue. The press release emphasizes that the information provided is not for official filing purposes and outlines the company’s forward-looking statements, which involve plans to regain compliance and continue meeting NYSE standards. These statements are based on current expectations but are subject to numerous risks and uncertainties that could impact the company’s future, including industry volatility, legal proceedings, and the success of new products and platforms.
For a thorough assessment of DNA stock, go to TipRanks’ Stock Analysis page.
